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Abstract
Background: In summer 2003 a disease management program (DMP) for type 2 diabetes was introduced on a
nationwide basis in Germany. Patient participation and continuity of care within the DMP are important factors to
achieve long-term improvements in clinical endpoints. Therefore it is of interest, if patients experience any positive
or negative effects of the DMP on their treatment that would support or hamper further participation. The main
objective of the study was to find out if the German Disease Management Program (DMP) for type 2 diabetes
improves process and outcome quality of medical care for patients in the light of their subjective experiences over
a period of one year.
Methods: Cohort study with a baseline interview and a follow-up after 10.4 ± 0.64 months. Data on process and
outcome measures were collected by telephone interviews with 444 patients enrolled and 494 patients not
enrolled in the German DMP for type 2 diabetes. Data were analyzed by multivariate logistic regression analyses.
Results: DMP enrolment was significantly associated with a higher process quality of care. At baseline enrolled
patients more often reported that they had attended a diabetes education course (OR = 3.4), have ≥ 4 contacts/
year with the attending physician (OR = 3.3), have at least one annual foot examination (OR = 3.1) and one referral
to an ophthalmologist (OR = 3.4) and possess a diabetes passport (OR = 2.4). Except for the annual referral to an
ophthalmologist these parameters were also statistically significant at follow-up. In contrast, no differences between
enrolled and not enrolled patients were found concerning outcome quality indicators, e.g. self-rated health,
Glycated hemoglobin (GHb) and blood pressure. However, 16-36% of the DMP participants reported improvements
of body weight and/or GHb and/or blood pressure values due to enrolment - unchanged within one year of
follow-up.
Conclusions: In the light of patient’s experiences the DMP enhances the process quality of medical care for type 2
diabetes in Germany. The lack of significant differences in outcome quality between enrolled and not enrolled
patients might be due to the short program duration. Our data suggest that the DMP for type 2 diabetes should
not be withdrawn unless an evidently more promising approach is found.
* Correspondence: kaduszki@uke.uni-hamburg.de
1Department of Primary Medical Care, Center of Psychosocial Medicine,
University Medical Center Hamburg-Eppendorf, Martinistr 52, 20246
Hamburg, Germany
Schäfer et al. BMC Health Services Research 2010, 10:55
http://www.biomedcentral.com/1472-6963/10/55
© 2010 Schäfer et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Health care improvement for patients with type 2 dia-
betes is an important target of health care policy in Ger-
many. In summer 2003 a disease management program
(DMP) for type 2 diabetes was introduced on a nation-
wide basis within the statutory health insurance, which
covers 86% of the German population. Participation in
the DMP is voluntary for physicians and patients and
connected with financial incentives for both provided by
the statutory health insurances. These in turn promote
participation heavily as they also obtain a significant
financial benefit for every enrolled patient [1]. Accord-
ing to latest data in January 2006 75% of the general
practitioners (GPs) in Germany participated in the DMP
[2]. 6 years after the start of the DMP, in August 2009,
approximately 64% of the estimated five million compul-
sorily insured patients with type 2 diabetes were
enrolled into the program [3]. Medical services in the
DMP include a defined frequency of visits to the attend-
ing physician, rules for referral to a diabetologist, regular
foot and eye examinations, physician counseling regard-
ing lifestyle changes (e.g. nutrition, smoking, exercise),
participation in diabetes education courses and agree-
ment on target values for Glycated hemoglobin (GHb)
and blood pressure between physician and patient.
Further elements of the program are the documentation
of the course of disease and treatment every 3-6
months, reminders for physicians and patients and a
continuous evaluation of the DMP [4].
A description of the history and design of the German
D M Pi sf o u n di nv a r i o u sp a p e r s[ 1 , 4 - 6 ] .T h ei n t r o d u c -
tion of the DMP in Germany was strongly criticized by
physicians associations and other organizations. It was
forwarded that evidence for the effectiveness of the pro-
gram was lacking and that the official program evalua-
tion was not methodologically sound due to the lack of
a control group [7]. Till today, the effectiveness of the
DMP has not yet been satisfactorily demonstrated. In
the meantime, an analysis of health insurance claims
data comparing enrolled and not enrolled patients indi-
cates that process quality of diabetes care is better for
enrolled patients [8]. Concerning outcome quality there
is no evidence of effectiveness, yet. It is assumed that
patient participation and continuity of care within the
DMP are important factors to achieve long-term
improvements in clinical endpoints. Therefore it is of
interest, if patients experience any positive or negative
effects of the DMP on their treatment that would sup-
port or hamper further participation. Furthermore
before the introduction of the DMP many doctors
feared a constriction of their therapeutic freedom result-
ing in a loss of the possibility to treat patients individu-
ally with negative consequences on the patient-doctor
relationship [9]. It is also of interest, if these fears
became true. The only published study examining the
subjective experiences in diabetes care of enrolled and
n o te n r o l l e dp a t i e n t ss h o w e dm a n i f o l dd i f f e r e n c e s
between the groups pointing to a better care for
enrolled patients [10], but the differences between the
groups were small and - with one exception - the ana-
lyses were not controlled for important confounders,
e.g. the duration of diabetes disease or the presence of
depressive symptoms. The only multivariate analysis
with health satisfaction as outcome emphasizes how
important this would have been. The analysis shows
that besides being a DMP participant also male sex,
higher school education, older age (70-79 vs. 45-59
years), and a self-rated low severity of diabetes disease
were significantly associated with higher health satisfac-
tion [11]. Changes in the subjective experiences of
patients over time were not investigated [10,11].
Thus, the main objective of the study was to find out
if in the view of patients with type 2 diabetes the Ger-
man DMP improves medical care over the period of one
year. This objective is related to both process and out-
come quality. We presumed that both, process and out-
come quality would be better in enrolled than in not
enrolled patients.
In addition we wanted to know, if enrolled patients
experience benefits which they directly attribute to the
DMP and we wanted to learn about the attitudes of not
enrolled patients towards enrolment. Finally, we were
interested to learn if certain groups of patients experi-
ence more benefits than others.
Methods
To assess differences between diabetes care within the
German DMP for type 2 diabetes and practice as usual
we performed telephone interviews with enrolled and
not enrolled patients twice with a follow-up period of
10.4 ± 0.64 months. Concerning process quality we
investigated whether according to the experiences of the
patients the medical services defined in the DMP (e.g.
education courses for diabetes, referrals to an ophthal-
mologist etc.) were delivered by the attending
physicians.
Regarding outcome quality both data on subjective
outcomes (e.g. self rated health, treatment satisfaction
and burden of therapy) and objective diabetes related
parameters (GHb, blood pressure, body mass index, foot
lesions, present symptoms of diabetes, smoking status,
and hypoglycaemia in the past 12 months) were col-
lected and compared.
All collected data on indicators of process and out-
come quality are listed in Table 1. In addition patient
reported data were also collected on:
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Page 2 of 12Table 1 Descriptive analysis of patient reported process and outcome indicators at baseline and follow-up
Process indicators DMP-patients
(baseline)
Patients not
enrolled
(baseline)
p
(baseline)
DMP-patients
(follow-up)
Patients not
enrolled
(follow-up)
p
(follow-up)
Participation in training program for diabetes 322 (72.7%) 222 (45.1%) p ≤ 0.001 250 (71.8%) 181 (52.8%) p ≤ 0.001
≥4 encounters/year with physician 398 (98.8%) 361 (75.5%) p ≤ 0.001 321 (92.5%) 280 (82.8%) p ≤ 0.001
Annual referral to an ophthalmologist 411 (93.0%) 380 (78.2%) p ≤ 0.001 318 (92.4%) 281 (83.9%) p ≤ 0.001
≥1 annual referral to a diabetologist
(GP patients only)
43 (13.1%) 44 (10.7%) n.s. 24 (9.6%) 26 (9.4%) n.s.
Specialty of the attending physician:
diabetologist
113 (25.5%) 73 (14.9%) p ≤ 0.001 100 (28.6%) 64 (18.6%) p ≤ 0.01
Annual foot examination 380 (86.2%) 324 (66.9%) p ≤ 0.001 307 (88.2%) 246 (73.2%) p ≤ 0.001
Possession of a diabetes passport 345 (78.1%) 287 (59.1%) p ≤ 0.001 276 (79.3%) 210 (61.8%) p ≤ 0.001
Nutritional advice given by physician 116 (29.6%) 98 (23.0%) p ≤ 0.05 71 (25.2%) 69 (26.7%) n.s.
Physician advice given on exercising 116 (32.9%) 80 (22.5%) p ≤ 0.01 79 (33.1%) 66 (30.1%) n.s.
Agreement upon target value for GHb 316 (77.3%) 295 (72.8%) p ≤ 0.05 244 (79.0%) 219 (79.3%) n.s.
Agreement upon target values for blood
pressure
326 (78.2%) 339 (76.9%) n.s. 255 (76.6%) 232 (76.6%) n.s.
Participation in education course for
hypertension
50 (11.3%) 33 (6.7%) p ≤ 0.05 43 (12.3%) 33 (9.7%) n.s.
Outcome indicators
Low self-rated health (1-4 on a 6-point scale) 171 (38.6%) 215 (43.7%) n.s. 149 (42.6%) 147 (42.6%) n.s.
(1-4 on a 6-point scale) 64 (14.5%) 74 (15.4%) n.s. 52 (14.8%) 60 (17.5%) n.s.
High burden of therapy (5-6 on a 6-point scale) 3 (0.7%) 11 (2.2%) n.s. 4 (1.1%) 4 (1.2%) n.s.
High self-rated ability to cope with disease
(5-6 on a 6-point scale)
419 (94.8%) 445 (91.9%) n.s. 319 (92.2%) 319 (93.3%) n.s.
High self-reported therapy adherence
(5-6 on a 6-point scale)
323 (72.9%) 349 (70.9%) n.s. 244 (69.7%) 240 (70.0%) n.s.
Mean GHb (%) 6.9 (SD: 0.9;
n = 330)
6.9 (SD: 1.3;
n = 287)
n.s. 6.9 (SD: 0.9;
n = 245)
6.8 (SD:1.1;
n = 200)
n.s.
high GHb [> 7.5% (> 8.5% for age 75+)] 72 (21.8%) 52 (18.1%) n.s. 46 (18.8%) 35 (17.5%) n.s.
Mean blood pressure (mm Hg) 132/79
(SD: 14.0/8.7;
n = 360)
135/80 (SD: 14.9/
9.1; n = 398/397)
p ≤ 0.05 133/80 (SD:
13.9/8.2
n = 293)
133.9/81 (SD: 14.3/
9.5 n = 276)
n.s.
high blood pressure (≥ 140/90 mm Hg) 137 (38.1%) 186 (46.7) p ≤ 0.05 129 (44%) 116 (42%) n.s.
Mean body mass index (kg/m
2) 29.7 (SD: 4.8;
n = 440)
29.4 (SD: 5.3;
n = 482)
n.s. 29.5 (SD: 9.1
n = 351)
28.3 (SD: 10.9
n = 342)
n.s.
high BMI (BMI ≥ 30 kg/m
2) 188 (42.7%) 191 (39.6%) n.s. 149 (42.5%) 137 (40.1%) n.s.
Diabetic foot lesions 45 (10.2%) 49 (10.0%) n.s. 29 (8.3%) 29 (8.5%) n.s.
Present symptoms of diabetes 153 (36.1%) 173 (35.8%) n.s. 108 (31.1%) 126 (36.8%) n.s.
Current smoker 74 (16.7%) 82 (16.6%) n.s. 56 (16.0%) 61 (17.7%) n.s.
Hypoglycemia in the past 12 months 26 (5.9%) 29 (6.0%) n.s. 23 (6.6%) 12 (3.6%) n.s.
Insulin treatment 153 (34.5%) 129 (26.3%) p ≤ 0.01 130 (37%) 107 (31%) n.s.
Increased cardiovascular risk [GHb ≥ 7.5%
(≥ 8.5% for age 75+) and/or blood pressure
≥ 140/90 mm Hg]
186 (56.9%) 221 (66.2%) ≤0.05 147 (56.5%) 136 (60.2%) n.s.
Not knowing GHb test results 72 (16.3%) 166 (33.9%) p ≤ 0.001 59 (16.9%) 97 (28.3%) p ≤ 0.001
Not knowing blood pressure values 39 (8.8%) 50 (10.1%) p ≤ 0.05 13 (3.7%) 30 (8.7%) p ≤ 0.01
n.s. = statistically not significant (p > 0.05)
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Page 3 of 12◦ the duration of diabetes in months/years,
◦ depression (using a screening test based on PHQ-2
questionnaire [12], resulting in a score of 0-6, with ≥
3 points raising suspicion of depression),
◦ the specialty of the regularly attending physician
(GP or diabetologist),
◦ the type of diabetes specific medication (insulin
with or without oral medication, oral medication
only or no medication at all),
◦ the patient’s level of education according to the
CASMIN classification [13],
◦ the interviewer-rated German language skills of the
patients and
◦ age and gender.
Furthermore, enrolled patients were asked to assess
the benefits of the DMP experienced by them (the ques-
tions asked are listed in Figure 1) and not enrolled
Figure 1 Patient-reported benefits of treatment in a DMP (enrolled patients only*). * Variations in the sample size of 444 enrolled patients
at baseline and 351 enrolled at follow-up are due to 1) patients, who formally had been enrolled in the program, but did not remember this in
the interview and 2) patients, whose enrollment data at timepoint of the interview were wrong and who therefore were not asked these
questions.
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ment in a DMP.
Patient recruitment
Probands were selected from the database of the Gmün-
der ErsatzKasse (GEK), a statutory health insurance
nationwide operating for 1.5 million members. Inclusion
criteria for the study were a medical diagnosis of type 2
diabetes (defined by an ICD-10 code of E11, E12 or
E14) by a primary care physician or a specialist and a
minimum age of 40 years in order to minimize the
inclusion of patients with type 1 diabetes. In addition,
the “enrolled” patients had to be enrolled in the DMP
for at least six months at time of the interview. The not
enrolled patients in our survey should have never been
enrolled in the DMP. The patients were randomly
selected from the database in a consecutive way, con-
tacted by telephone and - if possible - interviewed.
Interviews were performed by a professional medical
call-center (ife Gesundheits-AG, located in Nehmten).
All interviewers were physicians instructed by members
of the study group.
In total 2776 patients were contacted for the baseline
interview and 995 patients were interviewed (500
enrolled and 495 not enrolled in a DMP). In the course
of the project more detailed data on the enrolment sta-
tus of the patients became available from the insurance
company, including the exact enrollment date. In order
to assure inclusion quality, the initial assignment of
patients to the enrolment status was revised. The revi-
sion resulted in an assignment of 444 interviewed
patients to the group of enrolled patients and 494 to the
group of not enrolled patients. In sum 938 patients were
included in the analyses. 138 contacted patients could
not be assigned to any group as they did not fulfill the
inclusion criteria at baseline any more. These were
patients whose participation in the DMP had finished or
patients who had been participating in the DMP for less
than 6 months at timepoint of interview. At follow-up
approximately one year later (mean 10.4 months, SD
0.64, range 8-13 months), 696 (74.2%) of the 938
patients could be interviewed again. These 696 patients
were included into the follow-up analyses due to an
i n t e n t i o nt ot r e a ta p p r o a c h ,i . e .a l s op a r t i c i p a n t sw h o
had changed groups at follow-up were analyzed accord-
ing to their assignment at baseline. Figure 2 shows the
patient-flow through the study.
Non-responder analysis
All patients selected from the database of the GEK who
were not interviewed were considered as non-respon-
ders. Based on the GEK claims data no significant differ-
ences between responders (interviewed patients; n =
995) and non-responders (n = 1781) regarding age, sex
and most diabetes related diagnoses (glomerular disor-
ders, chronic renal failure, peripheral angiopathy, disor-
ders of lipoprotein metabolism, chronic stroke, chronic
ischemic heart disease, and heart failure) were found.
In the group of responders, slightly more patients suf-
fered from hypertension (80.4 vs. 71.6%; p ≤ 0.001), dia-
betic retinopathy (9.6 vs. 6.9%; p ≤ 0.01) and were
insulin-dependent (29.5 vs. 20.7%; p ≤ 0.001), but stayed
fewer days in hospital (mean total days in hospital: 3.0 ±
8.8 vs. 3.8 ± 11.2; p ≤ 0.05). Furthermore, responders
had received more prescriptions of different drugs
within one year (mean total number of different drug
p r e s c r i p t i o n s :8 . 3±4 . 8v s .7 . 5±5 . 2 ;p≤ 0.001), which
can be interpreted as a gross indicator of greater mor-
bidity. In short, the non-responder analysis showed that
an explicit selection bias in the direction of a greater
morbidity of non-responders did not occur.
Ethical approval
The study was approved by the Ethics Committee of the
Chamber of Physicians of Hamburg (reference number
OB-008/07).
Statistical Analyses
For the description of the sample, univariate tests of sig-
nificance (t-test and chi-square test) were performed. In
these analyses we applied the usual significance levels of
p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001. In addition, process
and outcome indicators of enrolled and not enrolled
patients were compared by multivariate logistic regres-
sion analyses. Odds ratios (OR) for all variables that
reached the p ≤ 0.001 significance level were calculated.
Age, sex, education, German language skills, duration of
diabetes and signs of depression were used as control
variables. We also calculated differences in high risk sta-
tus between enrolled and not enrolled patients. A high
risk status was assumed if a patient had GHb ≥ 7.5%
(≥ 8.5% for patients ≥ 75 years) and/or blood pressure
≥ 140/90 mmHg. These criteria were chosen according
to the “GP’s handbook” [14], the official national
evidence-based guideline for the type 2 diabetes DMP.
Multivariate logistic regression analyses with the above
mentioned control variables were also performed for an
analysis of the association of patient characteristics with
patient-reported benefits of treatment in a DMP and the
attitude towards enrolment in not enrolled patients. In
addition the duration of DMP participation was included
as control variable in the analyses with enrolled patients,
as it could influence the perceived benefits of treatment.
For each statistical model we used backward selection
algorithms (based on likelihood ratio) to identify interac-
tors (effect modifiers) within all possible two-factor
terms of exposure and control variables (p ≤ 0.005 for
exclusion; p ≤ 0.001 for re-inclusion). Interactors were
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0.001) after adjusting for all control variables. The final
statistical analyses contained all exposure variables, all
control variables and significant interactors. For the ana-
lysis of the follow-up data, the raw score of the depen-
dent variable at baseline was included as another
control variable, where appropriate.
As the data analyses are mainly explorative, we used
rigorous criteria to minimize the number of false posi-
tive results. For all multivariate logistic regression ana-
lyses an a-level of 0.1% (p ≤ 0.001) was defined as
statistically significant. All statistical tests were con-
ducted with SPSS 16.0.
Results
In our sample DMP and usual care patients did not dif-
fer in age, gender, level of education and German
language skills. Also, there was no difference between
enrolled and not enrolled patients concerning the dura-
tion of diabetes (see Table 2).
The DMP-effect was assessed by comparing process
and outcome indicators between enrolled and not
enrolled patients for baseline and follow-up. Descriptive
data are shown in Table 1, the results of the multivari-
ate logistic regression analyses are presented in Table 3.
Differences in process and outcome indicators at baseline
Regarding process measures we found that enrolment in
the DMP was significantly associated with a more fre-
quent utilization of type 2 diabetes-specific medical ser-
vices. Enrolled patients more often
- had participated in training programs for diabetes,
- had ≥ 4 encounters/year with their physician,
DMP-enrolled Patients  Not enrolled Patients 
 wrong contact data* 
145 (17.6%) 
refused to participate  
110 (13.3%) 
no type 2 diabetes
§
19 (2.3%) 
not accessible† 
19 (2.3%) 
other reasons 
89 (10.8%)
sample for baseline
#
1812 (100%) 
interviewed 
345 (69.8%) 
interviewed at 
baseline 444 (53.8%) 
interviewed 
351 (79.1%) 
interviewed at 
baseline 494 (27.3%) 
sample for follow-up 
444 (100%) 
sample for follow-up 
494 (100%) 
sample for baseline
#
826 patients (100%)   wrong contact data* 
289 (15.9%) 
refused to participate  
325 (17.9%) 
no type 2 diabetes
§
358 (19.8%) 
not accessible† 
39 (2.2%) 
other reasons 
307 (16.9%) 
 wrong contact data*
16 (3.6%) 
refused to participate  
25 (5.6%) 
not accessible† 
2 (0.5%) 
deceased 
2 (0.5%) 
other reasons 
48 (10.8%)
 wrong contact data*
14 (2.8%) 
refused to participate  
55 (11.1%) 
not accessible† 
6 (1.2%) 
deceased 
0 
other reasons 
74 (15.0%)
Figure 2 Description of sampling and response rate for baseline and follow-up. * wrong contact data, although the telephone numbers of
the insurants were updated using accessible public databases. † not accessible = not personally accessible despite 10 attempts with defined
time intervals of up to 7 days.
# 138 further patients were in the baseline sample but could not be assigned to any group when more detailed
enrollment data were available in the course of data analysis. 57 of these patients were interviewed at baseline and 39 reinterviewed at follow-
up. Their interviews were not included into the analyses.
§ according to patient; among enrolled patients: 14 (1,7%) no diabetes, 5 (0,6%)
diabetes type 1; among not enrolled patients: 307 (16,9%) no diabetes, 51 (2,8%) diabetes type 1.
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ophthalmologist,
- reported that the mainly attending physician was a
diabetologist,
- had at least one annual foot examination and
- possessed a diabetes passport (all p ≤ 0.001).
These differences were statistically significant both in
the descriptive and the multivariate logistic regression
analyses. Other differences regarding process measures
disappeared in the multivariate analyses after adjusting
for selected control variables. This holds for the fre-
quency of nutritional advice and advice on exercising by
their physician, the frequency of agreement on a target
value for GHb and the participation in educational
trainings for hypertension.
Aside being enrolled in the DMP the duration of the
diabetes was associated with three process measures:
The longer the patients had their diagnosis of diabetes,
the greater was the probability of having participated in
a training program for diabetes, of being mainly treated
by a diabetologist and possessing a diabetes passport.
Three other indicators of process quality were not asso-
ciated with DMP enrollment, but associated with age:
younger patients more often received a referral to a dia-
betologist/year, more often got an advice on exercising
and more often had agreed on a target value for GHb
than older patients.
In contrast to the measures of process quality, no dif-
ferences between enrolled and not enrolled patients
were found for the outcome measures self-rated health,
treatment satisfaction, burden of therapy, self-rated
adherence to medical therapy and the ability to cope
with the disease. Also there were no differences for
GHb, body mass index, smoking status, hypoglycemia in
the past 12 months, frequency of foot lesions and pre-
sence of diabetic symptoms, neither in the univariate
nor in the multivariate analyses.
In the univariate analyses self-reported blood pressure
was slightly higher in not enrolled patients (135/80 vs.
132/79 in enrolled patients), more of the enrolled
patients were treated with insulin (34.5 vs. 26.3%), and
less of the enrolled had an increased cardiovascular risk
(56.9 vs. 66.2%), but these differences disappeared in the
multivariate analyses. However, a higher percentage of
not enrolled patients did not know their test results for
GHb (33.9 vs. 16.3%; p ≤ 0.001) and blood pressure
(10.1 vs. 8.8%; p ≤ 0.05). Not knowing GHb test results
was the only outcome difference that was statistically
significant both in the univariate and in the multivariate
analyses at baseline.
A higher depression score was a significant confoun-
der concerning more subjectively coloured outcome
indicators. A high depression score was associated with
low self-rated health, the perception of present diabetes
symptoms, the perceived pr e s e n c eo fd i a b e t i cf o o t
lesions and a low self rated ability to cope with the dis-
ease. Also, age was a significant confounder: older age
was associated with a higher self-reported adherence to
therapy, not knowing the GHb test results, not smoking
and a lower body-mass index.
Differences in process and outcome indicators
at follow-up
The analysis of the follow-up data confirmed the results
of the baseline. In the multivariate analyses differences
between enrolled and not enrolled patients were only
found for parameters of process quality. Enrolled
patients more often
￿ had participated in training programs for diabetes,
￿ had at least 4 encounters/year with their physician,
￿ had at least one annual foot examination and
￿ possessed a diabetes passport.
Compared to the baseline, the difference between
enrolled and not enrolled patients with regard to at least
one annual referral to an ophthalmologist and being
mainly treated by a diabetologist did not reach statistical
significance. Interestingly most of the outcome measures
at follow-up were strongly associated with the respective
outcome measures at baseline.
Table 2 Sociodemographic data of enrolled and not enrolled patients at baseline
Patients enrolled in DMP (N = 444) Patients not enrolled (N = 494) p
Age mean (SD) 63.8 (8.49) 63 (10.1) n.s.
Men (%) 275 (61.9%) 302 (61.1%) n.s.
Level of Education: N = 420 N = 474 n.s.
- high (%) 276 (65.7%) 325 (68.6%)
- middle (%) 107 (25.5%) 111(23.4%)
- low (%) 37 (8.8%) 38 (8.0%)
Inferior German language skills (%) 30 (6.8%) 28 (5.7%) n.s.
Mean duration of diabetes (in years) (SD) N = 437
8.6 (7.45)
N = 485
8.04 (6.88)
n.s.
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Page 7 of 12Table 3 Association of enrolment in the DMP with patient reported process and outcome indicators, results of the
logistic regression analyses
Baseline Follow-up
Process indicators Odds Ratio (95%
confidence interval)
Significant confounders R
2 Odds Ratio (95%
confidence interval)
Significant
confounders
R
2
Participation in education
course for diabetes
3.4 (2.5-4.6) diabetes duration (longer) 0.173 2.1 (1.5-3.0) diabetes duration
(longer)
0.118
≥4 encounters/year with
physician
3.3 (2.2-5.1) None 0.097 3.1 (1.8-5.3) None 0.071
Annual referral to an
ophthalmologist
3.4 (2.2-5.4) Depr. score (lower) 0.134 n.s. None 0.066
≥1 referral to diabetologist/
year (GP patients only)
n.s. Age (younger) 0.124 n.s. None 0.024
Specialty of the attending
physician: diabetologist
2.0 (1.4-2.9) diabetes duration (longer) 0.090 n.s. None 0.048
Annual foot examination 3.1 (2.2-4.4) None 0.083 3.2 (2.0-4.9) None 0.082
Possession of a diabetes
passport
2.4 (1.7-3.2) diabetes duration (longer) 0.110 2.1 (1.5-3.0) None 0.058
Nutritional advice given by
physician
n.s. None 0.021 n.s. None 0.032
Physician advice given on
exercising
n.s. Age (younger) 0.071 n.s. None 0.030
Agreement on target value
for GHb
n.s. Age (younger) 0.092 n.s. Age (younger) 0.091
Agreement upon target
values for blood pressure
n.s. None 0.015 n.s. None 0.023
Participation in education
course for hypertension
n.s. None 0.025 n.s. None 0.018
Outcome Indicators
Self-rated health (S-rh) (low) n.s. Depr. score (higher) 0.165 n.s. Depr. score (higher),
S-rh at t0 (lower)
0.200
Satisfaction with medical
treatment (low)
n.s. None 0.028 n.s. Satisf. with med.
treatment t0 (lower)
0.119
Burden of therapy (high) n.s. None 0.125 n.s. None 0.078
Self-rated ability to cope with
disease (high)
n.s. Depr. score (lower), language
skills (better)
0.120 n.s. Depr. score (lower) 0.017
Self-reported therapy
adherence (S-rta) (high)
n.s. Age (older), language skills
(better)
0.080 n.s. S-rta at t0 (higher),
Depr. score (lower)
0.138
GHb [≥ 7.5% (≥ 8.5% for age
75+)]
n.s. diabetes duration (longer) 0.070 n.s. GHb level at t0 (high) 0.365
Blood pressure (≥ 140/90
mm Hg)
n.s. None 0.052 n.s. Blood pressure at t0
(high)
0.231
Body mass index (≥ 30 kg/
m
2)
n.s. Age (younger), sex (female) 0.067 n.s. BMI at t0 (high) 0.726
Diabetic foot lesions (Dfl) n.s. Depr. score (higher) 0.073 n.s. Dfl at t0, depr. score
(higher)
0.193
Present symptoms of
diabetes
n.s. Depr. score (higher) 0.144 n.s. Depr. score (higher) 0.117
Smoking n.s. Age (younger) 0.157 n.s. Status as smoker at t0 0.808
Risk of hypoglycemia (high) n.s. None 0.079 n.s. None 0.163
Insulin treatment n.s. diabetes duration (longer) 0.227 n.s. Insulin treatment at t0 0.839
Increased cardiovascular risk* n.s. Education (lower) 0.097 n.s Increased
cardiovascular risk at
t0
0.262
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Enrolled patients were asked whether their participation in
the DMP had resulted in a change of their medical treat-
ment for diabetes. At baseline and at follow-up, the major-
ity of DMP participants did not report any change (70%),
whereas 29% reported that their treatment had improved
due to enrolment. Approximately one third of the enrolled
indicated a decrease of their GHb and a decrease of body
weight due to enrolment - at both interviews. 19% at base-
line and 16% at follow-up reported a decrease of blood
pressure. Asked for a global rating of perceived benefit of
the DMP, the patients’ opinion was very positive: 54% of
the patients at baseline and 50% at follow-up saw a high to
very high benefit on a 6 point scale, 23% (and 34% at fol-
low-up) a moderate benefit. About one fifth of enrolled
patients perceived low, very low or no benefit of the pro-
gram at both interviews (see Figure 1).
Analyzing the association of patient socio-demographic
characteristics with reported improvements of treatment
due to DMP enrolment at baseline, we found that a low
depression score was associated with reporting a general
improvement of the medical treatment due to enrolment
(OR 1.4 for each point less in the depression score, 95%
CI 1.02-2.0, p ≤ 0.05). Female gender was associated with
reporting an improvement of GHb test results (OR 2.5,
95% CI 1.4-4.6, p ≤ 0.01) and a short duration of the dia-
betes was associated with reporting an improvement of
body weight (OR 1.1 for each year less of diabetes, 95%
CI 1.01-1.1, p ≤ 0.05).
At the time of follow-up, a reported improvement of
the respective parameter at baseline was associated with
reported improvements in the medical treatment (OR
3.0, 95% CI 1.5-6.0, p ≤ 0.01), improvement of GHb test
results (OR 2.5, 95% CI 1.2-5.1, p ≤ 0.05), of body weight
(OR 4.5, 95% CI 2.2-9.0, p ≤ 0.001), and of blood pres-
sure (OR 2.9, 95% CI 1.2-6.8, p ≤ 0.05). Reporting an
improvement of body weight at follow-up also was asso-
ciated with a short duration of the diabetes (OR 1.1 for
each year less of diabetes, 95% CI 1.01-1.135, p ≤ 0.05).
In sum, female patients, patients with a shorter dura-
tion of their diabetes (and presumably a lower severity
of their type 2 diabetes), and patients with lower levels
of depression more often regarded the DMP as benefi-
cial at baseline. At follow-up, patients who had reported
benefits at baseline still saw improvements.
Attitude towards enrolment in a DMP
At baseline, 29% of the not enrolled patients said that they
would like to participate in the DMP, whereas 59% said
they would not like to do so. 12% of the not enrolled sta-
ted that they had never heard of the DMP (n = 323). The
results from the follow-up interviews are similar: At fol-
low-up 26% of the patients who were not enrolled at base-
line and follow-up said that they would like to participate
in the DMP, whereas 58% not. 16% of the not enrolled
stated that they had never heard of the DMP (n = 141).
A positive attitude towards enrolment was associated with
higher education at baseline (OR 3.6, 95% CI 1.4-9.2,
p ≤ 0.01). At follow-up those who had articulated a wish
for enrolment at baseline more often reported this wish -
again (OR 5.0, 95% CI 1.7-14.4, p ≤ 0.01).
Discussion
In the view of patients with type 2 diabetes the German
DMP improves parameters of process quality of care.
Enrolled patients show a more frequent utilization of the
services defined in the DMP: patient education courses for
diabetes, regular encounters with the physician, referrals
to the ophthalmologist and annual foot examinations.
Also they more frequently possess a diabetes passport.
The finding that more enrolled patients are mainly
attended by a diabetologist can be interpreted as an indica-
tor of process quality but also as an indicator of overusage
of specialists. The German DMP only defines criteria for
referral but does not intend to shift the main treatment
responsibility to specialists. Except for referrals to the
ophthalmologist and specialty of the attending physician
the parameters statistically significant at baseline were also
statistically significant one year later. These findings are in
line with those of Szecsenyi et al. [15]. In their postal sur-
vey of 1.399 patients those enrolled in the DMP reported
of a more structured care that reflected the core elements
of the chronic care model than those not enrolled. They
are also in line with an analysis of out-patient claims data
Table 3: Association of enrolment in the DMP with patient reported process and outcome indicators, results of the
logistic regression analyses (Continued)
Knowing GHb test results 2.8 (2.0-4.0) age (younger), language skills
(better), diabetes duration
(longer)
0.186 n.s. Knowing GHb test
results at t0
0.289
Knowing blood pressure test
results
n.s. None 0.034 n.s. Knowing blood
pressure at t0
0.216
Multivariate logistic regression analyses. Enrolled patients compared to not enrolled patients adjusted for age, sex, education, duration of diabetes disease,
German language skills and depressive symptoms. In addition outcome indicators at follow-up controlled for baseline values (t0). Direction of association is
indicated in brackets; p ≤ 0.001 for all odds ratios shown as numerical values; n.s. = statistically not significant (p > 0.001). *Increased cardiovascular risk = [GHb
≥ 7.5% (≥ 8.5% for age 75+) and/or blood pressure ≥ 140/90 mm Hg]; Depr. = Depression
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health insurance, by Graf et al. [16]. They compared
claims data of around 80.000 insurants who never partici-
pated in a DMP with around 81.000 insurants who were
continuously enrolled since 2005. Among others the data
revealed that enrolled patients had visited a patient train-
ing program for type 2 diabetes, had seen an ophthalmolo-
gist and a diabetologist more frequently than not enrolled
patients.
With the higher frequency of these services one could
expect an improvement in outcome variables. Research
has shown varying evidence for the effectiveness of
DMPs on outcomes depending on the outcome para-
meter in question. Patient education can improve ther-
apy adherence and the ability to deal with the disease in
every day life [17] as well as foster short-term improve-
ments in GHb [18] and blood pressure levels [19]. Nor-
ris et al. forwarded strong evidence that disease
management interventions are effective in improving
glycaemic control [20]. Other studies with single-group,
pre-post designs with 2-year follow-up also showed sig-
nificant improvements in glycaemic control [21] and in
the vascular risk profile (GHb, blood pressure and blood
lipids) [22]. In contrast, diabetes passports do not seem
to have much impact on outcome measures [23,24] and
a Cochrane Review on adherence to treatment in
patients with type 2 diabetes did not find significant
effects of current inter-ventions [25]. The effect of dis-
ease management on quality of life has not been studied
thoroughly yet [20,26].
In our study, however, no outcome differences between
enrolled and not enrolled patients were found in the mul-
tivariate analyses, except for the risk of not knowing GHb
test results at baseline being higher in the not enrolled
group. These results must be interpreted with caution
because we do not know whether there were differences
between enrolled and not enrolled patients at the time of
enrolment. Interestingly most of the outcome measures
at follow-up were strongly associated with the respective
outcome measures at baseline, which indicates a low
impact of the DMP on changing outcomes within one
year of follow-up. It is also possible, that the program
duration of at maximum 3.5 years at the time of the
interview was insufficient to demonstrate outcome quality
differences. Another reason for the lack of outcome dif-
ferences might be the complex nature of outcome indica-
tors that are dependent on a great number of factors
beyond the process quality of medical care, e.g. the socio-
demographic situation. To sum up, indicators of process
quality seem to be more easily changed by the DMP than
indicators of outcome quality.
Despite the lack of outcome quality differences, 16 to
36% of the DMP participants reported that the medical
treatment of their diabetes, GHb, blood pressure values
and/or their body weight had improved due to enrol-
ment. Especially female patients, patients with a shorter
duration of their diabetes (and presumably a lower sever-
ity of their type 2 diabetes), and patients with lower levels
of depression more often regarded the DMP as beneficial
at baseline. At follow-up, patients who had reported ben-
efits at baseline still saw improvements.
Negative effects of the DMP were reported rarely and
were most frequent for an increase of body weight (in
10% of DMP participants at baseline and 12% at follow-
up). Moreover, in the descriptive analyses, enrolled
patients more often knew their GHb and blood pressure
values. In sum, substantial outcome differences between
enrolled and non-enrolled patients were not found in
the multivariate analyses but around one third of the
patients perceives a subjective outcome benefit of the
DMP - unchanged within one year of follow-up.
Concerning the attitude towards enrolment around
60% of not enrolled patients at both interviews stated
that they would not like to be enrolled. Hypotheses why
patients do not wish to be enrolled mostly refer to the
idea of “problem patients”,i . e .n o ta c t i v ea n dn o tm o t i -
vated patients with a low therapy adherence. However,
reasons for not-enrolment of patients have not yet been
investigated in a methodologically sound manner.
The multivariate analyses revealed important confoun-
ders of enrolment in the DMP, which should always be
controlled for in studies that analyse the effectiveness of
the program. For example, patients with a longer dura-
tion of their diabetes, which might be an indicator for
higher disease severity, show a more frequent utilization
of the services defined in the DMP - independently of
their enrolment status. Patients screened positive for
depression show worse outcomes in subjective outcome
indicators like self-rated health than patients without
depression. Younger age is associated e.g. with a higher
body-mass index and smoking, older age with better self-
reported adherence to therapy, but lack of knowledge of
GHb test results, when controlled for all other factors.
Strengths of our study are the multivariate analyses
that controlled for important confounders of enrolment
in the DMP, the interpretation of differences as statisti-
cally significant only if p ≤ 0.001 and the intention-to-
treat analysis at follow-up. This leads to a conservative
estimation of differences between enrolled and not
enrolled patients and thus of the effects of the DMP.
Therefore we regard the differences found in process
measures as robust. In contrast to the analyses of Graf
et al. [16] and Elkeles et al. [10,11], we also included
type 2 diabetes patients who did not (yet) use any dia-
betes specific medication (15.8% of the enrolled and
19.4% of the not enrolled patients at baseline). There-
fore, the results can be considered as valid for all
patients with type 2 diabetes.
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not enrolled (72.7%) than enrolled patients (46.2%)
could not be interviewed at baseline. Twice more not
enrolled than enrolled patients had wrong contact data
(N = 289 vs. 145) and three times more not enrolled
patients refused to participate in the study (N = 325 vs.
110). Also 307 of the not enrolled patients in the base-
line sample drawn by the insurance company denied to
have diabetes although they had been identified by an
ICD-10 code of E11, E12 or E14 in the insurance claims
data. In enrolled patients these were only 14. The non-
responder analysis revealed that the non-responders did
not have a greater morbidity. In sum, for unknown rea-
sons not enrolled patients were more difficult to recruit
for this study. This might have biased the results. At fol-
low-up, the same problem occurred to a lower degree:
30.2% of not enrolled patients could not be re-inter-
viewed vs. 20.9% of the enrolled patients. Another weak-
ness of our study is that the total sample included more
men than women (61.5% men, p < 0.001). The low per-
centage of women in the whole sample is due to the his-
torical structure of the GEK, which till the nineties was
a special insurance company for craftsman (and their
families). This specialty in the member structure of the
GEK might limit the generalization of the results for all
patients insured in the statutory health insurance in
Germany. Additionally most enrolled and not enrolled
patients we recruited had a high education level which
indicates a selection bias in the direction of higher edu-
cated patient groups in our study. Against the back-
ground of evidence for a higher degree of education in
enrolled patients [27] this bias might especially affect
not enrolled patients. If this was true, the differences in
process quality found are a conservative estimation as
process quality is better for patients with higher educa-
tion. Finally, another weakness of our study is that
patient-reported data especially of clinical outcomes
might not be valid. A collection of clinical data based
on chart review would have been better, but was not
realizable within this project. Therefore the lacking out-
come differences between enrolled and not enrolled
patients should not be interpreted in the sense of a
non-effectiveness of the German DMP.
Some results of the descriptive analyses also deserve
consideration. Mean GHb values in our study of 6.9%
and blood pressure values of around 134/80 (both for
the enrolled and the not enrolled) appear to be good.
Concerning GHb they are comparable with the results
of the DETECT study (6.9 ± 1.2%), a huge epidemiologi-
cal german study. Regarding blood pressure the values
in our study are even lower than in the DETECT study:
140.6 ± 18.3 mmHg [28]. However, the percentage of
patients with an increased cardiovascular risk profile -
defined as GHb ≥ 7.5% and ≥ 8.5% for age 75+ and/or
blood pressure ≥ 140/90 mm Hg - is around 60% in all
patients. This indicates that there is still a potential for
improvement. The same applies to a percentage of
around 17% smokers and around 35% of patients who
report to be highly thirsty and/or suffer from frequent
urination and/or from fatigue.
Conclusions
In January 2009, the funding of the DMPs was reduced
in the course an overall financial reform of the health
insurance system in Germany. Statutory health insur-
ances now have to decide whether to continue the DMP
or to find another way of structuring care according to
the needs of chronically ill patients. Our data suggest
that due to the experiences of the patients the DMP for
type 2 diabetes enhances process quality of diabetes
care. It should not be withdrawn unless an evidently
more promising approach is found.
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